AU2016264323B2 - Compositions and methods for TCR reprogramming using fusion proteins - Google Patents

Compositions and methods for TCR reprogramming using fusion proteins Download PDF

Info

Publication number
AU2016264323B2
AU2016264323B2 AU2016264323A AU2016264323A AU2016264323B2 AU 2016264323 B2 AU2016264323 B2 AU 2016264323B2 AU 2016264323 A AU2016264323 A AU 2016264323A AU 2016264323 A AU2016264323 A AU 2016264323A AU 2016264323 B2 AU2016264323 B2 AU 2016264323B2
Authority
AU
Australia
Prior art keywords
cell
domain
tcr
tfp
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016264323A
Other languages
English (en)
Other versions
AU2016264323A8 (en
AU2016264323A1 (en
Inventor
Patrick Baeuerle
Robert Hofmeister
Gregory Sieczkiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TCR2 Therapeutics Inc
Original Assignee
TCR2 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57320750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016264323(B2) "Global patent litigation datasetโ€ by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by TCR2 Therapeutics Inc filed Critical TCR2 Therapeutics Inc
Publication of AU2016264323A1 publication Critical patent/AU2016264323A1/en
Publication of AU2016264323A8 publication Critical patent/AU2016264323A8/en
Application granted granted Critical
Publication of AU2016264323B2 publication Critical patent/AU2016264323B2/en
Priority to AU2021203052A priority Critical patent/AU2021203052A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016264323A 2015-05-18 2016-05-18 Compositions and methods for TCR reprogramming using fusion proteins Active AU2016264323B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021203052A AU2021203052A1 (en) 2015-05-18 2021-05-13 Compositions and methods for TCR reprogramming using fusion proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163342P 2015-05-18 2015-05-18
US62/163,342 2015-05-18
PCT/US2016/033146 WO2016187349A1 (en) 2015-05-18 2016-05-18 Compositions and methods for tcr reprogramming using fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021203052A Division AU2021203052A1 (en) 2015-05-18 2021-05-13 Compositions and methods for TCR reprogramming using fusion proteins

Publications (3)

Publication Number Publication Date
AU2016264323A1 AU2016264323A1 (en) 2017-12-14
AU2016264323A8 AU2016264323A8 (en) 2017-12-21
AU2016264323B2 true AU2016264323B2 (en) 2021-02-18

Family

ID=57320750

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016264323A Active AU2016264323B2 (en) 2015-05-18 2016-05-18 Compositions and methods for TCR reprogramming using fusion proteins
AU2021203052A Abandoned AU2021203052A1 (en) 2015-05-18 2021-05-13 Compositions and methods for TCR reprogramming using fusion proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021203052A Abandoned AU2021203052A1 (en) 2015-05-18 2021-05-13 Compositions and methods for TCR reprogramming using fusion proteins

Country Status (19)

Country Link
US (7) US10442849B2 (cg-RX-API-DMAC7.html)
EP (3) EP3770168A1 (cg-RX-API-DMAC7.html)
JP (4) JP2018515123A (cg-RX-API-DMAC7.html)
KR (1) KR20180029201A (cg-RX-API-DMAC7.html)
CN (2) CN114634943A (cg-RX-API-DMAC7.html)
AU (2) AU2016264323B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017024757A2 (cg-RX-API-DMAC7.html)
DK (1) DK3298033T4 (cg-RX-API-DMAC7.html)
EA (2) EA202090931A3 (cg-RX-API-DMAC7.html)
ES (1) ES2819976T5 (cg-RX-API-DMAC7.html)
FI (1) FI3298033T4 (cg-RX-API-DMAC7.html)
HU (1) HUE051661T2 (cg-RX-API-DMAC7.html)
IL (2) IL255697B2 (cg-RX-API-DMAC7.html)
MX (1) MX2017014822A (cg-RX-API-DMAC7.html)
PL (1) PL3298033T5 (cg-RX-API-DMAC7.html)
PT (1) PT3298033T (cg-RX-API-DMAC7.html)
SG (1) SG10201914069SA (cg-RX-API-DMAC7.html)
WO (1) WO2016187349A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708000B (cg-RX-API-DMAC7.html)

Families Citing this family (104)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
SG10201808811QA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2017004252A1 (en) * 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
US12577289B2 (en) 2015-06-30 2026-03-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Surrogate co-receptors for t cells and methods of use
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle ChildrenยดS Hospital Dba Seattle ChildrenยดS Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
EP3359650A4 (en) * 2015-10-08 2019-03-20 Innovative Cellular Therapeutics Co., Ltd. ACTIVATION AND EXPANSION OF CELLS
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
US11365237B2 (en) * 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchenโ€”Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US10086055B2 (en) * 2016-06-01 2018-10-02 Promab Biotechnologies, Inc. Adherent cancer cell line expressing a hematological tumor antigen
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3516068B1 (en) 2016-09-19 2025-04-23 University of Southern California Non-radioactive cytotoxicity assays
WO2018064076A1 (en) 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composiรงรตes e mรฉtodos para reprogramaรงรฃo de receptores de cรฉlula t com o uso de proteรญnas de fusรฃo
CN110177803A (zh) 2016-11-22 2019-08-27 T็ป†่ƒžๅ—ไฝ“ๆฒป็–—ๅ…ฌๅธ ็”จไบŽไฝฟ็”จ่žๅˆ่›‹็™ฝ่ฟ›่กŒtcr้‡ๆ–ฐ็ผ–็จ‹็š„็ป„ๅˆ็‰ฉๅ’Œๆ–นๆณ•
CN110352068A (zh) * 2016-12-02 2019-10-18 ๅ—ๅŠ ๅˆฉ็ฆๅฐผไบšๅคงๅญฆ ๅˆๆˆ็š„ๅ…็–ซๅ—ไฝ“ๅŠๅ…ถไฝฟ็”จๆ–นๆณ•
CA3047999A1 (en) * 2016-12-21 2018-06-28 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
CN116120454A (zh) * 2017-01-05 2023-05-16 ไธŠๆตท็…ฆ้กผๆŠ€ๆœฏๆœ‰้™ๅ…ฌๅธ ไบบๆบๅŒ–ๆŠ—cd19ๆŠ—ไฝ“ๅŠๅ…ถไธŽๅตŒๅˆๆŠ—ๅŽŸๅ—ไฝ“็š„็”จ้€”
US20190375815A1 (en) * 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018166589A1 (en) 2017-03-15 2018-09-20 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
EP3615574B1 (en) 2017-04-26 2026-06-24 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
WO2018200582A1 (en) * 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
PL3618842T3 (pl) * 2017-05-01 2024-02-19 Juno Therapeutics, Inc. Kombinacja terapii komรณrkowej i zwiฤ…zku immunomodulujฤ…cego
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e mรฉtodos para cรฉlulas manipuladas e seus usos em imuno-oncologia
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
DK3688032T3 (da) 2017-09-26 2025-12-15 Cero Therapeutics Holdings Inc Kimรฆre engulfment-receptormolekyler og anvendelsesfremgangsmรฅder
BR112020005938A2 (pt) 2017-09-27 2020-11-17 University Of Southern California cรฉlula imune ou populaรงรฃo de cรฉlulas imunes da mesma, cรฉlula efetora imune ou cรฉlula-tronco, cรฉlula que apresenta antรญgeno, polinucleotรญdeo recombinante, vetor, composiรงรฃo que compreende uma cรฉlula imune efetora ou uma cรฉlula-tronco, mรฉtodos para produzir uma cรฉlula efetora imune que expressa receptor imune de ocorrรชncia nรฃo natural, para gerar uma populaรงรฃo de cรฉlulas manipuladas por rna, para fornecer imunidade antidoenรงa em um indivรญduo, para tratar ou prevenir uma doenรงa associada ร  expressรฃo de um antรญgeno, e, uso
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
CN110662771B (zh) 2018-02-01 2023-07-28 ๅ—ไบฌ้ฉฏ้นฟ็”Ÿ็‰ฉๆŠ€ๆœฏ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ไธ€็ง็ป“ๅˆbcma็š„ๅตŒๅˆๆŠ—ๅŽŸๅ—ไฝ“(car)ๅŠๅ…ถๅบ”็”จ
ES2968880T3 (es) * 2018-02-01 2024-05-14 Nanjing Iaso Biotechnology Co Ltd Receptor de antรญgeno quimรฉrico (CAR) que se une a BCMA, y usos del mismo
WO2019157279A1 (en) * 2018-02-10 2019-08-15 Berkeley Lights, Inc. Mutant idh1 specific t cell receptor
SG11202007622SA (en) 2018-02-11 2020-09-29 Memorial Sloan Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
BR112020016570A2 (pt) 2018-02-17 2020-12-15 Flagship Pioneering Innovations V, Inc. Composiรงรตes e mรฉtodos para liberaรงรฃo de proteรญna de membrana
CA3093449A1 (en) * 2018-03-09 2019-09-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
RU2020135107A (ru) 2018-03-28 2022-04-29 ะกะตั€ะพ ะขะตั€ะฐะฟัŒัŽั‚ะธะบั, ะ˜ะฝะบ. ะšะปะตั‚ะพั‡ะฝั‹ะต ะธะผะผัƒะฝะพั‚ะตั€ะฐะฟะตะฒั‚ะธั‡ะตัะบะธะต ะบะพะผะฟะพะทะธั†ะธะธ ะธ ะธั… ะฟั€ะธะผะตะฝะตะฝะธั
MX2020010235A (es) 2018-03-28 2020-10-28 Cero Therapeutics Inc Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
US12291557B2 (en) 2018-03-28 2025-05-06 Cero Therapeutics Holdings, Inc. Chimeric TIM4 receptors and uses thereof
US20200063100A1 (en) 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer
JP7599205B2 (ja) 2018-06-01 2024-12-13 ใ‚ขใƒณใƒ˜ใƒฌใ‚น ใ‚ปใƒฉใƒ”ใƒฅใƒผใƒ†ใ‚ฃใ‚ฏใ‚น ใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ็ดฐ่ƒž็™‚ๆณ•ใฎใŸใ‚ใฎๅคšๆง˜ใชๆŠ—ๅŽŸ็ตๅˆใƒ‰ใƒกใ‚คใƒณใ€ๆ–ฐ่ฆใƒ—ใƒฉใƒƒใƒˆใƒ•ใ‚ฉใƒผใƒ ใŠใ‚ˆใณใใฎไป–ใฎๅผทๅŒ–
WO2019242632A1 (en) * 2018-06-19 2019-12-26 1ยง1Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
KR20210031898A (ko) * 2018-07-13 2021-03-23 ๋‚œ์ง• ๋ ˆ์ „๋“œ ๋ฐ”์ด์˜คํ…Œํฌ ์”จ์˜ค., ์—˜ํ‹ฐ๋””. ์ „์—ผ๋ณ‘์„ ์น˜๋ฃŒํ•˜๊ธฐ ์œ„ํ•œ ๊ณต๋™์ˆ˜์šฉ์ฒด ์‹œ์Šคํ…œ
SG11202100838QA (en) * 2018-07-26 2021-02-25 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using target specific fusion proteins
CN113573719A (zh) 2018-11-08 2021-10-29 ๆœฑ่ฏบๆฒป็–—ๅญฆ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๆฒป็–—ๅ’Œt็ป†่ƒž่ฐƒ่Š‚็š„ๆ–นๆณ•ๅ’Œ็ป„ๅˆ
KR20210131991A (ko) 2018-11-14 2021-11-03 ํ”Œ๋ž˜๊ทธ์‰ฝ ํŒŒ์ด์–ด๋‹ˆ์–ด๋ง ์ด๋…ธ๋ฒ ์ด์…˜์Šค ๋ธŒ์ด, ์ธํฌ. ๊ตฌํš-ํŠน์ด์  ์นด๊ณ  ์ „๋‹ฌ์„ ์œ„ํ•œ ์กฐ์„ฑ๋ฌผ ๋ฐ ๋ฐฉ๋ฒ•
CN109735558B (zh) * 2018-12-12 2022-04-15 ไธญๅ—ๅคงๅญฆ ไธ€็ง้‡็ป„car19-il24ๅŸบๅ› ใ€ๆ…ข็—…ๆฏ’่ฝฝไฝ“ใ€car19-il24-t็ป†่ƒžๅŠๅบ”็”จ
US20230192805A1 (en) * 2019-01-14 2023-06-22 Nanjing Legend Biotech Co., Ltd. Chimeric receptor polypeptides and uses thereof
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
EP3715368A1 (en) 2019-03-28 2020-09-30 Albert-Ludwigs-Universitรคt Freiburg Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells
WO2020201527A1 (en) 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
EP3959322A4 (en) * 2019-04-22 2023-06-07 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3138633A1 (en) 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
WO2020243158A1 (en) * 2019-05-28 2020-12-03 The University Of Vermont And State Agricultural College Gamma-delta t cell ligands for cancer immunotherapy
WO2020264269A1 (en) 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gรชnica relacionada
EP3999079A4 (en) * 2019-07-19 2024-04-03 Memorial Sloan Kettering Cancer Center Fusion polypeptide for immunotherapy
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN112500492B (zh) * 2019-09-13 2023-08-04 ไธญๅ›ฝ็ง‘ๅญฆ้™ขๅˆ†ๅญ็ป†่ƒž็ง‘ๅญฆๅ“่ถŠๅˆ›ๆ–ฐไธญๅฟƒ ไธ€็งๅตŒๅˆๆŠ—ๅŽŸๅ—ไฝ“ๅŠๅ…ถ็”จ้€”
US20240058446A1 (en) 2019-10-03 2024-02-22 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
AU2020382219A1 (en) 2019-11-13 2022-05-12 Crispr Therapeutics Ag Manufacturing process for making T cells expressing chimeric antigen receptors
CN110964122B (zh) * 2019-12-24 2022-04-15 ๅ—ไบฌๅŒ—ๆ’็”Ÿ็‰ฉ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ T็ป†่ƒžๅ—ไฝ“่žๅˆ่›‹็™ฝๅŠๅ…ถ็”จ้€”
WO2021188599A1 (en) 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
WO2021198163A1 (en) * 2020-04-01 2021-10-07 Medigene Immunotherapies Gmbh Cd3-fusion protein and uses thereof
WO2021226289A2 (en) * 2020-05-05 2021-11-11 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
EP4185326A1 (en) * 2020-07-24 2023-05-31 TCR2 Therapeutics Inc. Compositions and methods for treating cancer
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
JP7868033B2 (ja) 2020-08-14 2026-06-01 ใ‚ปใƒญใƒปใ‚ปใƒฉใƒ”ใƒฅใƒผใƒ†ใ‚ฃใ‚ฏใ‚นใƒปใƒ›ใƒผใƒซใƒ‡ใ‚ฃใƒณใ‚ฐใ‚นใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ใ‚ญใƒกใƒฉ๏ฝ”๏ฝ‰๏ฝๅ—ๅฎนไฝ“ใŠใ‚ˆใณใใฎไฝฟ็”จ
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
EP4243937A2 (en) 2020-11-13 2023-09-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
CN112521513B (zh) * 2020-12-15 2021-08-24 ้’ๅฒ›่ฅฟๅ‡ฏ็”Ÿ็‰ฉๆŠ€ๆœฏๆœ‰้™ๅ…ฌๅธ ไธ€็ง้ถๅ‘cd19็š„ๅตŒๅˆๆŠ—ๅŽŸๅ—ไฝ“(car)ๅŠๅ…ถๅบ”็”จ
TW202241935A (zh) 2020-12-18 2022-11-01 ็พŽๅ•†ไธ–็ด€ๆฒป็™‚่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๅ…ทๆœ‰ๅฏ่ชฟ้ฉๅ—้ซ”ๅฐˆไธ€ๆ€งไน‹ๅตŒๅˆๆŠ—ๅŽŸๅ—้ซ”็ณป็ตฑ
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
WO2022174172A1 (en) * 2021-02-15 2022-08-18 H. Lee Moffitt Cancer Center And Research Institute Inc. Customized chimeric antigen receptor polypeptides
WO2022177966A1 (en) * 2021-02-16 2022-08-25 TCR2 Therapeutics Inc. Compositions and methods for the treatment of hiv
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2022192286A1 (en) * 2021-03-09 2022-09-15 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins and rna interference
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
FI4376874T3 (fi) 2021-07-28 2026-04-08 Cero Therapeutics Holdings Inc Kimeerisiรค tim4-reseptoreita ja niiden kรคyttรถjรค
JP2024531915A (ja) 2021-08-05 2024-09-03 ใ‚ธใƒผใ‚ชใƒผ ใ‚ปใƒฉใƒ”ใƒฅใƒผใƒ†ใ‚ฃใ‚ฏใ‚น๏ผŒใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ๆŠ—ใ‚ฐใƒชใ‚ณ๏ฝ๏ฝ•๏ฝƒๆŠ—ไฝ“ใŠใ‚ˆใณใใฎไฝฟ็”จ
WO2023010436A1 (zh) * 2021-08-05 2023-02-09 ๅก็‘žๆตŽ(ๅŒ—ไบฌ)็”Ÿๅ‘ฝ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ Tcr่กจ่พพๆž„ๅปบไฝ“ไปฅๅŠๅ…ถๅˆถๅค‡ๆ–นๆณ•ๅ’Œ็”จ้€”
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
JP2024534910A (ja) 2021-09-03 2024-09-26 ใ‚ธใƒผใ‚ชใƒผ ใ‚ปใƒฉใƒ”ใƒฅใƒผใƒ†ใ‚ฃใ‚ฏใ‚น๏ผŒใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ๆŠ—ใ‚ฐใƒชใ‚ณ๏ฝŒ๏ฝ๏ฝ๏ฝ๏ผ‘ๆŠ—ไฝ“ใŠใ‚ˆใณใใฎไฝฟ็”จ
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
US20250009800A1 (en) 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2023108150A1 (en) 2021-12-10 2023-06-15 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
IL321936A (en) 2023-01-05 2025-09-01 Prec Biosciences Inc Optimized engineered meganucleases with specificity for the human T-cell receptor alpha constant region gene
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024259371A2 (en) * 2023-06-14 2024-12-19 Duke University COMPOSITIONS FOR AND METHODS OF EXPANDING ฮณฮด T CELLS
WO2025029930A1 (en) 2023-07-31 2025-02-06 Legend Biotech Ireland Limited Cells overexpressing cd31 and methods of use thereof
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2025212850A1 (en) 2024-01-26 2026-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025162379A1 (zh) * 2024-02-01 2025-08-07 ๆทฑๅœณๅธ‚ๆตŽๅ› ็”Ÿ็‰ฉ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ ไธ€็งๅคš่‚ฝๅŠๅŒ…ๅซๆ‰€่ฟฐๅคš่‚ฝๅŸบๅ› ็š„็—…ๆฏ’่ฝฝไฝ“
WO2026035951A2 (en) 2024-08-07 2026-02-12 Legend Biotech Ireland Limited Cells overexpressing cd43 and methods of use thereof
WO2026055226A1 (en) 2024-09-03 2026-03-12 Legend Biotech Ireland Limited Cells overexpressing b3gnt2 and methods of use thereof

Citations (1)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258720A1 (en) * 2009-05-19 2010-12-08 Max Delbrรผck Centrum fรผr Molekulare Medizin (MDC) Berlin-Buch; Multiple target T cell receptor

Family Cites Families (269)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US1009390A (en) 1910-04-18 1911-11-21 Miehle Printing Press & Mfg Manufacture of printing-plates.
US1035847A (en) 1910-05-23 1912-08-20 William P Bettendorf Means for cushioning the bodies of railway-cars.
US1020828A (en) 1911-12-11 1912-03-19 William A Rees Electric washing-machine.
US1044284A (en) 1912-04-29 1912-11-12 Gen Electric Heating device.
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Systรจme d'aimant ร  entrefer annulaire
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5906936A (en) * 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenitรคt der variablen Antikรถrperdomรคnen
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
WO1993019163A1 (en) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) * 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
MXPA01011950A (es) 1999-05-27 2002-05-06 Gov Health & Human Serv Inmunoconjugados que tienen alta afinidad de enlace.
WO2000077029A1 (en) 1999-06-16 2000-12-21 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. ็ป†่ƒž็š„ๅŒๆญฅๅˆบๆฟ€ๅ’ŒๅฏŒ้›†
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US6822082B2 (en) 2000-06-30 2004-11-23 Zymogenetics, Inc. Polynucleotides for mammalian secreted protein, Z1055G2P
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
CN1294148C (zh) 2001-04-11 2007-01-10 ไธญๅ›ฝ็ง‘ๅญฆ้™ข้—ไผ ไธŽๅ‘่‚ฒ็”Ÿ็‰ฉๅญฆ็ ”็ฉถๆ‰€ ็Žฏ็Šถๅ•้“พไธ‰็‰นๅผ‚ๆŠ—ไฝ“
JP4213586B2 (ja) 2001-09-13 2009-01-21 ๆ ชๅผไผš็คพๆŠ—ไฝ“็ ”็ฉถๆ‰€ ใƒฉใ‚ฏใƒ€ๆŠ—ไฝ“ใƒฉใ‚คใƒ–ใƒฉใƒชใƒผใฎไฝœ่ฃฝๆ–นๆณ•
AU2003208839A1 (en) 2002-02-13 2003-09-04 Micromet Ag De-immunized (poly)peptide constructs
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universitรคt Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7251470B2 (en) 2003-06-25 2007-07-31 Nokia Corporation Emergency response system with personal emergency device
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US20050042664A1 (en) 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
DE602004027291D1 (de) 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikรถrper und immunkonjugate
US20050238626A1 (en) 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
WO2006018833A2 (en) 2004-08-16 2006-02-23 Tadiran Spectralink Ltd. A wearable device, system and method for measuring a pulse while a user is in motion
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP2322560B1 (en) 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
WO2006124641A2 (en) 2005-05-12 2006-11-23 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Anti-mesothelin antibodies useful for immunological assays
KR20140053410A (ko) 2005-08-19 2014-05-07 ์•„๋ณดํŠธ ๋Ÿฌ๋ณด๋Ÿฌํ„ฐ๋ฆฌ์ฆˆ ์ด์› ๊ฐ€๋ณ€ ๋„๋ฉ”์ธ ๋ฉด์—ญ๊ธ€๋กœ๋ถˆ๋ฆฐ ๋ฐ ์ด์˜ ์šฉ๋„
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
GB0721686D0 (en) 2007-11-05 2007-12-12 Medinnova As Polypeptides
KR101559599B1 (ko) 2007-11-26 2015-10-12 ๋ฐ”์ด์—˜ ์ธํ…”๋ ‰์ณ ํ”„๋กœํผํ‹ฐ ๊ฒŒ์— ๋ฒ ํ•˜ ํ•ญ-๋ฉ”์†Œํ…”๋ฆฐ ํ•ญ์ฒด ๋ฐ ์ด์˜ ์šฉ๋„
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
KR20090092900A (ko) 2008-02-28 2009-09-02 ์‹ ์ค€ํ˜ธ ์–ด๋ฆฐ์ด ๋ฐ ๋…ธ์•ฝ์ž ์•ˆ์ „๋ณดํ˜ธ์‹œ์Šคํ…œ
US20090322513A1 (en) 2008-06-27 2009-12-31 Franklin Dun-Jen Hwang Medical emergency alert system and method
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
KR101837053B1 (ko) 2008-10-01 2018-03-12 ์•”์   ๋ฆฌ์„œ์น˜ (๋ฎŒํ—จ) ๊ฒŒ์— ๋ฒ ํ•˜ ์ข…๊ฐ„ ํŠน์ด์  ๏ผฐ๏ผณ๏ผฃ๏ผก๏ฝ˜๏ผฃ๏ผค๏ผ“, ๏ผฃ๏ผค19๏ฝ˜๏ผฃ๏ผค3, ๏ฝƒ-๏ผญ๏ผฅ๏ผด๏ฝ˜๏ผฃ๏ผค3, ์—”๋„์‹œ์•Œ๋ฆฐ๏ฝ˜๏ผฃ๏ผค3, ๏ผฅ๏ฝ๏ผฃ๏ผก๏ผญ๏ฝ˜๏ผฃ๏ผค3, ๏ผฉ๏ผง๏ผฆ-1๏ผฒ๏ฝ˜๏ผฃ๏ผค3 ๋˜๋Š” ๏ผฆ๏ผก๏ผฐฮฑ๏ฝ˜๏ผฃ๏ผค3 ์ด์ค‘ํŠน์ด์  ๋‹จ์ผ์‡„ ํ•ญ์ฒด
HUE043326T2 (hu) * 2008-11-07 2019-08-28 Amgen Res Munich Gmbh Akut limfoblasztos leukรฉmia kezelรฉse
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
CN102421801B (zh) * 2009-03-10 2016-03-16 ๆฏ”ๅฅฅๆ นMaๅ…ฌๅธ ๆŠ—-bcmaๆŠ—ไฝ“
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
US20130066283A1 (en) 2009-10-23 2013-03-14 Nexisvision, Inc. Corneal Denervation for Treatment of Ocular Pain
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
LT2361936T (lt) 2010-02-25 2016-09-12 Affimed Gmbh Antigenฤ… riลกanti molekulฤ— ir jos panaudojimas
CA2793753C (en) 2010-03-26 2018-06-05 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
WO2012008860A2 (en) 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
EP2614143B1 (en) 2010-09-08 2018-11-07 Baylor College Of Medicine Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
CA2816379A1 (en) 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
EP3018145B1 (en) 2010-10-27 2018-04-04 Amgen Research (Munich) GmbH Means and methods for treating dlbcl
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
JP2014509841A (ja) 2011-01-18 2014-04-24 ใ‚ถ ใƒˆใƒฉใ‚นใƒ†ใ‚ฃใƒผใ‚บ ใ‚ชใƒ– ใ‚ถ ใƒฆใƒ‹ใƒใƒผใ‚ทใƒ†ใ‚ฃ ใ‚ชใƒ– ใƒšใƒณใ‚ทใƒซใƒใƒ‹ใ‚ข ็™Œใ‚’ๆฒป็™‚ใ™ใ‚‹ใŸใ‚ใฎ็ต„ๆˆ็‰ฉใŠใ‚ˆใณๆ–นๆณ•
ES2588730T3 (es) 2011-03-17 2016-11-04 Miltenyi Biotec Gmbh Preparados celulares agotados en lo que respecta a TCRalfa/beta
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
KR20140060541A (ko) 2011-09-16 2014-05-20 ๋” ํŠธ๋Ÿฌ์Šคํ‹ฐ์Šค ์˜ค๋ธŒ ๋” ์œ ๋‹ˆ๋ฒ„์‹œํ‹ฐ ์˜ค๋ธŒ ํŽœ์‹ค๋ฐ”๋‹ˆ์•„ ์•”์„ ์น˜๋ฃŒํ•˜๊ธฐ ์œ„ํ•œ rna ์กฐ์ž‘๋œ t ์„ธํฌ
JP6074435B2 (ja) 2011-10-26 2017-02-01 ใƒŠใ‚ทใƒงใƒŠใƒซ ใ‚ญใƒฃใƒณใ‚ตใƒผ ใ‚ปใƒณใ‚ฟใƒผ ๅค‰็•ฐ๏ฝƒ๏ฝ”๏ฝŒ๏ฝ๏ผ”้บไผๅญ็งปๅ…ฅ๏ฝ”็ดฐ่ƒžๅŠใณใ“ใ‚Œใ‚’ๅซใ‚€ๆŠ—ใŒใ‚“ๅ…็–ซๆฒป็™‚็”จ็ต„ๆˆ็‰ฉ
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
TWI679212B (zh) 2011-11-15 2019-12-11 ็พŽๅ•†ๅฎ‰้€ฒ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ้‡ๅฐ๏ฝ‚๏ฝƒ๏ฝ๏ฝไน‹e3ไปฅๅŠ๏ฝƒ๏ฝ„๏ผ“็š„็ตๅˆๅˆ†ๅญ
AR089114A1 (es) 2011-12-09 2014-07-30 Amgen Res Munich Gmbh PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
BR112014020502A2 (pt) 2012-02-22 2019-09-24 Univ Pennsylvania sequรชncia de รกcido nucleico isolada, receptor quimรฉrico de antรญgeno isolado, cรฉlula, vetor, e, mรฉtodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamรญfero, para gerar e para expandir uma populaรงรฃo de cรฉlulas - t, e para modular a quantidade de citocina secretada por uma cรฉlula -t
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
CA2868121C (en) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
AU2013246443B2 (en) * 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
US9127081B2 (en) 2012-05-10 2015-09-08 Washington University Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
KR20150029714A (ko) 2012-07-13 2015-03-18 ๋” ํŠธ๋Ÿฌ์Šคํ‹ฐ์Šค ์˜ค๋ธŒ ๋” ์œ ๋‹ˆ๋ฒ„์‹œํ‹ฐ ์˜ค๋ธŒ ํŽœ์‹ค๋ฐ”๋‹ˆ์•„ ์ด์ค‘ํŠน์ด์  ํ•ญ์ฒด์˜ ๊ณต-๋„์ž…์— ์˜ํ•œ ๏ฝƒ๏ฝ๏ฝ’ ์„ธํฌ์˜ ํ™œ์„ฑ ์ฆ๊ฐ•
KR20210149195A (ko) 2012-07-13 2021-12-08 ๋” ํŠธ๋Ÿฌ์Šคํ‹ฐ์Šค ์˜ค๋ธŒ ๋” ์œ ๋‹ˆ๋ฒ„์‹œํ‹ฐ ์˜ค๋ธŒ ํŽœ์‹ค๋ฒ ๋‹ˆ์•„ ํ˜•์งˆ๋„์ž…๋œ ๏ฝ” ์„ธํฌ์˜ ํˆฌ์—ฌ ์ ํ•ฉ์„ฑ์„ ํ‰๊ฐ€ํ•˜๋Š” ๋ฐฉ๋ฒ•
EP2872617A4 (en) 2012-07-13 2015-12-09 Univ Pennsylvania EPITOP SPREADING IN CONNECTION WITH CAR T CELLS
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Lฤ…stelinฤ—s imunoterapijos bลซdas ir kompozicijos
US9416190B2 (en) 2012-09-27 2016-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
RU2729401C2 (ru) 2012-10-02 2020-08-06 ะœะตะผะพั€ะธะฐะป ะกะปะพะฐะฝ-ะšะตั‚ั‚ะตั€ะธะฝะณ ะšัะฝัะตั€ ะกะตะฝั‚ะตั€ ะšะพะผะฟะพะทะธั†ะธะธ ะธ ัะฟะพัะพะฑั‹ ะดะปั ะธะผะผัƒะฝะพั‚ะตั€ะฐะฟะธะธ
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US9562110B2 (en) 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
JP6636803B2 (ja) 2013-02-05 2020-01-29 ใ‚จใƒณใ‚ฏใƒžใƒ• ใ‚จใ‚นใ‚ขใƒผใ‚จใƒผใƒซใ‚จใƒซ ๏ผข๏ฝƒ๏ฝ๏ฝใซๅฏพใ™ใ‚‹ๆŠ—ไฝ“ใฎ้ธๆŠžใฎใŸใ‚ใฎๆ–นๆณ•
SG11201507026WA (en) 2013-02-06 2015-10-29 Anthrogenesis Corp Modified t lymphocytes having improved specificity
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
WO2014130635A1 (en) * 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2014134412A1 (en) 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
US20160015749A1 (en) 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
AU2014386824B2 (en) 2013-03-15 2019-05-09 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Molรฉculas de uniรณn para bcma y cd3
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
EP2970372B1 (en) 2013-03-15 2020-09-30 Celgene Corporation Modified t lymphocytes
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor ฮฒ
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cรกncer utilizando un receptor quimรฉrico de antรญgeno anti-cd19
EP3789487A1 (en) 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
US11311575B2 (en) 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
SI2997141T1 (sl) 2013-05-13 2023-04-28 Cellectis CD19 specifiฤni himerni antigenski receptor in njegova uporaba
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
JP6608807B2 (ja) 2013-05-29 2019-11-20 ใ‚ปใƒฌใ‚ฏใƒ†ใ‚ฃใ‚น ๏ผฒ๏ฝŽ๏ฝใ‚ฌใ‚คใƒ‰๏ฝƒ๏ฝ๏ฝ“ใƒŒใ‚ฏใƒฌใ‚ขใƒผใ‚ผ็ณปใ‚’็”จใ„ใ‚‹ใ“ใจใซใ‚ˆใฃใฆๅ…็–ซ็™‚ๆณ•ใฎใŸใ‚ใซ๏ฝ”็ดฐ่ƒžใ‚’ๆ“ไฝœใ™ใ‚‹ใŸใ‚ใฎๆ–นๆณ•
BR112016000666A2 (pt) 2013-07-12 2017-10-03 Zymeworks Inc Constructos de ligaรงรฃo de antรญgeno cd3 e cd19 biespecรญficos
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
KR20250051130A (ko) 2013-09-25 2025-04-16 ์‹ธ์ดํ†ฐ์Šค ํ…Œ๋ผํ“จํ‹ฑ์Šค, ์ธํฌ. ๋งคํŠธ๋ฆญ์Šค ๋ฉ”ํƒˆ๋กœํ”„๋กœํ…Œ์ด๋‚˜์ œ ๊ธฐ์งˆ ๋ฐ ๋‹ค๋ฅธ ์ ˆ๋‹จ์„ฑ ๋ชจ์ด์–ดํ‹ฐ ๋ฐ ์ด์˜ ์‚ฌ์šฉ ๋ฐฉ๋ฒ•
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
AU2014337385B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Chimeric antigen receptor T cell switches and uses thereof
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
WO2015092024A2 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
AU2015206040B2 (en) 2014-01-14 2018-11-01 Cellectis Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
EP3097117B1 (en) * 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
TWI681969B (zh) 2014-01-23 2020-01-11 ็พŽๅ•†ๅ†็”Ÿๅ…ƒ้†ซ่—ฅๅ…ฌๅธ ้‡ๅฐ๏ฝ๏ฝ„-๏ผ‘็š„ไบบ้กžๆŠ—้ซ”
CA2936984A1 (en) 2014-01-24 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors
KR20240164967A (ko) 2014-02-04 2024-11-21 ์นด์ดํŠธ ํŒŒ๋งˆ ์ธ์ฝ”ํฌ๋ ˆ์ดํ‹ฐ๋“œ B ์„ธํฌ ์•…์„ฑ์ข…์–‘ ๋ฐ ๋‹ค๋ฅธ ์•”์„ ์น˜๋ฃŒํ•˜๋Š”๋ฐ ์œ ์šฉํ•œ ์ž๊ฐ€ t ์„ธํฌ ๋ฐ ๊ทธ์˜ ์กฐ์„ฑ๋ฌผ์˜ ์ƒ์‚ฐ ๋ฐฉ๋ฒ•
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimรฆre antigenreceptorer og fremgangsmรฅder til fremstilling heraf
JP6665102B2 (ja) 2014-02-21 2020-03-13 ใ‚ปใƒฌใ‚ฏใƒ†ใ‚ฃใ‚น๏ผฃ๏ฝ…๏ฝŒ๏ฝŒ๏ฝ…๏ฝƒ๏ฝ”๏ฝ‰๏ฝ“ ๅˆถๅพกๆ€ง๏ฝ”็ดฐ่ƒžใ‚’ใ‚คใƒณใ‚ตใ‚คใƒใƒฅใƒผใง้˜ปๅฎณใ™ใ‚‹ใŸใ‚ใฎๆ–นๆณ•
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
KR101605421B1 (ko) 2014-03-05 2016-03-23 ๊ตญ๋ฆฝ์•”์„ผํ„ฐ B ์„ธํฌ ๋ฆผํ”„์ข… ์„ธํฌ๋ฅผ ํŠน์ด์ ์œผ๋กœ ์ธ์ง€ํ•˜๋Š” ๋‹จ์ผํด๋ก ํ•ญ์ฒด ๋ฐ ์ด์˜ ์šฉ๋„
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
CN122399016A (zh) 2014-03-15 2026-07-17 ่ฏบๅŽ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ไฝฟ็”จๅตŒๅˆๆŠ—ๅŽŸๅ—ไฝ“ๆฒป็–—็™Œ็—‡
CN106459165B (zh) 2014-04-01 2021-04-20 ๆ‹œๆฉ็ง‘ๆŠ€็ป†่ƒž&ๅŸบๅ› ๆฒป็–—ๆœ‰้™ๅ…ฌๅธ ๅฏ†ๅฐ่›‹็™ฝ-6็‰นๅผ‚ๆ€งๅ…็–ซๅ—ไฝ“ๅ’Œt็ป†่ƒž่กจไฝ
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
WO2015164759A2 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Mnd promoter chimeric antigen receptors
CN106456670B (zh) 2014-04-25 2020-01-07 ่“้ธŸ็”Ÿ็‰ฉๅ…ฌๅธ ๅˆถๅค‡่ฟ‡็ปงๆ€ง็ป†่ƒž็–—ๆณ•็š„ๆ”นๅ–„ๆ–นๆณ•
EP3166968B1 (en) 2014-05-02 2021-09-22 The Trustees of the University of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
US11041021B2 (en) 2014-05-23 2021-06-22 University Of Florida Research Foundation, Incorporated Car based immunotherapy
US10287360B2 (en) 2014-05-23 2019-05-14 INSERM (Institut National de la Santรฉ et de la Recherche Mรฉdicale Anti-EGFR conformational single domain antibodies and uses thereof
WO2015188141A2 (en) 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
US10752684B2 (en) 2014-07-29 2020-08-25 Cellectis ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3177711B1 (en) 2014-08-07 2024-04-24 Northwestern University Use of ligands for the programmed cell death receptor conjugated to solid supports for the expansion of human regulatory t cells
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universitรคt Mรผnchen Subcutaneously administered bispecific antibodies for use in the treatment of cancer
EP3177640B1 (en) 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
CA2957929A1 (en) 2014-08-12 2016-02-18 Anthrogenesis Corporation Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimรฆriske antigenreceptorer til modificerede t-celler
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
WO2016040441A1 (en) 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
ES2738705T3 (es) 2014-09-19 2020-01-24 Hope City Linfocitos T de receptor de antรญgeno quimรฉrico coestimulante que se dirigen a IL13R 2
WO2016054520A2 (en) * 2014-10-03 2016-04-07 The California Institute For Biomedical Research Engineered cell surface proteins and uses thereof
AU2015330017A1 (en) 2014-10-07 2017-04-27 Cellectis Method for modulating car-induced immune cells activity
BR112017008042A2 (pt) 2014-10-20 2017-12-26 Juno Therapeutics Inc mรฉtodos e composiรงรตes para dosagem em terapia de cรฉlula adotiva
PL3212225T3 (pl) โ€  2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytรณw t
WO2016073381A1 (en) 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
JP6740234B2 (ja) 2014-11-05 2020-08-12 ใ‚ธใƒฅใƒŽใƒผ ใ‚ปใƒฉใƒ”ใƒฅใƒผใƒ†ใ‚ฃใ‚ฏใ‚น ใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ๅฝข่ณชๅฐŽๅ…ฅใŠใ‚ˆใณ็ดฐ่ƒžใƒ—ใƒญใ‚ปใ‚ทใƒณใ‚ฐใฎใŸใ‚ใฎๆ–นๆณ•
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
US10201606B2 (en) 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
EP3227323B1 (en) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
HRP20210582T1 (hr) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
DK3227339T3 (da) 2014-12-05 2022-01-10 Memorial Sloan Kettering Cancer Center Kimรฆriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf
CN113698497A (zh) 2014-12-05 2021-11-26 ็บชๅฟตๆ–ฏ้š†-ๅ‡ฏ็‰น็ณ็™Œ็—‡ไธญๅฟƒ ้ถๅ‘b-็ป†่ƒžๆˆ็†ŸๆŠ—ๅŽŸ็š„ๅตŒๅˆๆŠ—ๅŽŸๅ—ไฝ“ๅŠๅ…ถ็”จ้€”
US20170296623A1 (en) 2014-12-17 2017-10-19 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
EP3037170A1 (en) 2014-12-27 2016-06-29 Miltenyi Biotec GmbH Multisort cell separation method
RU2751362C2 (ru) 2014-12-29 2021-07-13 ะะพะฒะฐั€ั‚ะธั ะะณ ะกะฟะพัะพะฑั‹ ะฟะพะปัƒั‡ะตะฝะธั ัะบัะฟั€ะตััะธั€ัƒัŽั‰ะธั… ั…ะธะผะตั€ะฝั‹ะน ะฐะฝั‚ะธะณะตะฝะฝั‹ะน ั€ะตั†ะตะฟั‚ะพั€ ะบะปะตั‚ะพะบ
WO2016115274A1 (en) 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
GB201501175D0 (en) 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
EP3250611B1 (en) 2015-01-26 2021-04-21 The University of Chicago Car t-cells recognizing cancer-specific il 13r-alpha2
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016123675A1 (en) 2015-02-05 2016-08-11 The University Of Queensland Targeting constructs for delivery of payloads
AU2016215110A1 (en) 2015-02-05 2017-09-21 Stc.Unm Anti-pre-BCR antagonists and methods
US20160228547A1 (en) 2015-02-06 2016-08-11 Batu Biologics, Inc. Chimeric antigen receptor targeting of tumor endothelium
US10647778B2 (en) 2015-02-09 2020-05-12 University Of Florida Research Foundation, Incorporated Bi-specific chimeric antigen receptor and uses thereof
CA2974998C (en) 2015-02-12 2022-04-26 Takara Bio Inc. Chimeric antigen receptors
US20160237407A1 (en) 2015-02-17 2016-08-18 Batu Biologics, Inc. Universal donor chimeric antigen receptor cells
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP3262166A4 (en) 2015-02-24 2018-08-15 The Regents of The University of California Binding-triggered transcriptional switches and methods of use thereof
BR112017018770A2 (pt) 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. reduรงรฃo da tolerรขncia imunolรณgica induzida por pd-l1
SG11201707182WA (en) 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
KR20170134525A (ko) 2015-04-02 2017-12-06 ๋ฉ”๋ชจ๋ฆฌ์–ผ ์Šฌ๋กœ์•ˆ-์ผ€ํ„ฐ๋ง ์บ”์„œ ์„ผํ„ฐ Tnfrsf14 / hvem ๋‹จ๋ฐฑ์งˆ ๋ฐ ์ด์˜ ์ด์šฉ ๋ฐฉ๋ฒ•
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
PT3310805T (pt) 2015-06-19 2021-05-19 Kobold Sebastian Proteรญnas de fusรฃo pd-1-cd28 e a sua utilizaรงรฃo em medicina
JP6974311B2 (ja) 2015-06-23 2021-12-01 ใƒกใƒขใƒชใ‚ขใƒซ ใ‚นใƒญใƒผใƒณ ใ‚ฑใ‚ฟใƒชใƒณใ‚ฐ ใ‚ญใƒฃใƒณใ‚ตใƒผ ใ‚ปใƒณใ‚ฟใƒผ ๆ–ฐ่ฆ๏ฝ๏ฝ„โˆ’๏ผ‘ๅ…็–ซ่ชฟ็ฏ€ๅ‰ค
MX2018000278A (es) 2015-06-29 2018-03-08 Univ Johns Hopkins Terapia de receptores quimericos de puntos de control inmunitarios.
US11242375B2 (en) 2015-09-04 2022-02-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
CN106519037B (zh) 2015-09-11 2019-07-23 ็ง‘ๆตŽ็”Ÿ็‰ฉๅŒป่ฏ๏ผˆไธŠๆตท๏ผ‰ๆœ‰้™ๅ…ฌๅธ ๅฏๆดปๅŒ–็š„ๅตŒๅˆๅ—ไฝ“
ES2803728T3 (es) 2015-10-05 2021-01-29 Prec Biosciences Inc Cรฉlulas genรฉticamente modificadas que comprenden un gen de regiรณn constante alfa del receptor de linfocitos T humano modificado
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
CN105331585A (zh) 2015-11-13 2016-02-17 ็ง‘ๆตŽ็”Ÿ็‰ฉๅŒป่ฏ๏ผˆไธŠๆตท๏ผ‰ๆœ‰้™ๅ…ฌๅธ ๆบๅธฆpd-l1้˜ปๆ–ญๅ‰‚็š„ๅตŒๅˆๆŠ—ๅŽŸๅ—ไฝ“ไฟฎ้ฅฐ็š„ๅ…็–ซๆ•ˆๅบ”็ป†่ƒž
CN109072194B (zh) 2015-12-09 2022-12-27 ็บชๅฟตๆ–ฏ้š†-ๅ‡ฏ็‰นๆž—็™Œ็—‡ไธญๅฟƒ ๅ…็–ซ็ป†่ƒž็ป„ๅˆ็‰ฉๅŠๅ…ถไฝฟ็”จๆ–นๆณ•
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigรฉnio quimรฉrico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilizaรงรฃo combinada em terapia anticancerรญgena
CN108601841A (zh) 2016-02-10 2018-09-28 ๅ…็–ซๅŒป็–—ๅ…ฌๅธ Abcg2ๆŠ‘ๅˆถๅ‰‚ไธŽsacituzumab govitecan(immu-132)็š„็ป„ๅˆๅ…‹ๆœ่กจ่พพtrop-2็š„็™Œไธญๅฏนsn-38็š„ๆŠ—ๆ€ง
WO2017162587A1 (en) 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
US11365237B2 (en) 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchenโ€”Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
KR102427334B1 (ko) 2016-04-01 2022-08-03 ์นด์ดํŠธ ํŒŒ๋งˆ ์ธ์ฝ”ํฌ๋ ˆ์ดํ‹ฐ๋“œ ํ‚ค๋ฉ”๋ผ ํ•ญ์› ๋ฐ t ์„ธํฌ ์ˆ˜์šฉ์ฒด ๋ฐ ์‚ฌ์šฉ ๋ฐฉ๋ฒ•
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3034691A1 (en) 2016-08-30 2018-03-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
BR112019007100A2 (pt) * 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composiรงรตes e mรฉtodos para reprogramaรงรฃo de receptores de cรฉlula t com o uso de proteรญnas de fusรฃo
CN110177803A (zh) 2016-11-22 2019-08-27 T็ป†่ƒžๅ—ไฝ“ๆฒป็–—ๅ…ฌๅธ ็”จไบŽไฝฟ็”จ่žๅˆ่›‹็™ฝ่ฟ›่กŒtcr้‡ๆ–ฐ็ผ–็จ‹็š„็ป„ๅˆ็‰ฉๅ’Œๆ–นๆณ•
CA3047999A1 (en) 2016-12-21 2018-06-28 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
WO2018119198A1 (en) 2016-12-22 2018-06-28 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
EP3572427B1 (en) 2017-01-23 2025-06-25 CRAGE medical Co., Limited Bcma-targeting antibody and use thereof
WO2018189360A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
WO2018232020A1 (en) 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
BR112020005938A2 (pt) 2017-09-27 2020-11-17 University Of Southern California cรฉlula imune ou populaรงรฃo de cรฉlulas imunes da mesma, cรฉlula efetora imune ou cรฉlula-tronco, cรฉlula que apresenta antรญgeno, polinucleotรญdeo recombinante, vetor, composiรงรฃo que compreende uma cรฉlula imune efetora ou uma cรฉlula-tronco, mรฉtodos para produzir uma cรฉlula efetora imune que expressa receptor imune de ocorrรชncia nรฃo natural, para gerar uma populaรงรฃo de cรฉlulas manipuladas por rna, para fornecer imunidade antidoenรงa em um indivรญduo, para tratar ou prevenir uma doenรงa associada ร  expressรฃo de um antรญgeno, e, uso
GB201800298D0 (en) 2018-01-09 2018-02-21 Autolus Ltd Method
MX2020008184A (es) 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
CA3093449A1 (en) 2018-03-09 2019-09-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2019222275A2 (en) 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using inducible fusion proteins
SG11202100838QA (en) 2018-07-26 2021-02-25 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using target specific fusion proteins
KR102879284B1 (ko) 2018-08-29 2025-10-31 ๋‚œ์ง• ๋ ˆ์ „๋“œ ๋ฐ”์ด์˜คํ…Œํฌ ์”จ์˜ค., ์—˜ํ‹ฐ๋””. ํ•ญ-๋ฉ”์†Œํ…”๋ฆฐ ํ‚ค๋ฉ”๋ผ ํ•ญ์› ์ˆ˜์šฉ์ฒด(car) ์ž‘์ œ๋ฌผ ๋ฐ ์ด์˜ ์šฉ๋„
SG11202101811VA (en) 2018-08-30 2021-03-30 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using fusion proteins
CN114206357A (zh) 2019-03-22 2022-03-18 T็ป†่ƒžๅ—ไฝ“ๆฒป็–—ๅ…ฌๅธ ไฝฟ็”จ่žๅˆ่›‹็™ฝ่ฟ›่กŒtcr้‡็ผ–็จ‹็š„็ป„ๅˆ็‰ฉๅ’Œๆ–นๆณ•
EP3959322A4 (en) 2019-04-22 2023-06-07 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20210130438A1 (en) 2019-10-28 2021-05-06 The Broad Institute, Inc. Pan-cancer t cell exhaustion genes
US20230338421A1 (en) 2020-01-10 2023-10-26 TCR2 Therapeutics Inc. Compositions and methods for autoimmunity regulation
WO2021155034A1 (en) 2020-01-29 2021-08-05 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using muc16 specific fusion proteins
WO2021226289A2 (en) 2020-05-05 2021-11-11 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
EP4185326A1 (en) 2020-07-24 2023-05-31 TCR2 Therapeutics Inc. Compositions and methods for treating cancer
WO2022056321A1 (en) 2020-09-10 2022-03-17 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using gpc3 specific fusion proteins
WO2022177966A1 (en) 2021-02-16 2022-08-25 TCR2 Therapeutics Inc. Compositions and methods for the treatment of hiv
US20230065936A1 (en) 2021-04-09 2023-03-02 Tcr2 Therapeutics Inc Compositions and methods for treating cancer
WO2023044039A1 (en) 2021-09-16 2023-03-23 TCR2 Therapeutics Inc. Compositions and methods for treating cancer

Patent Citations (1)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258720A1 (en) * 2009-05-19 2010-12-08 Max Delbrรผck Centrum fรผr Molekulare Medizin (MDC) Berlin-Buch; Multiple target T cell receptor

Non-Patent Citations (1)

* Cited by examiner, โ€  Cited by third party
Title
Nolan, K.F. et al., "Bypassing Immunization: Optimized Design of "Designer T cells" against Carcinoembryonic Antigen (CEA)-expressing Tumours, and Lack of Suppression by Soluble CEA", Clinical Cancer Research, (1999) Vol. 5, pages 3928-3941 *

Also Published As

Publication number Publication date
KR20180029201A (ko) 2018-03-20
US10358473B2 (en) 2019-07-23
EP3298033B2 (en) 2023-07-12
IL303905A (en) 2023-08-01
US20200207828A1 (en) 2020-07-02
DK3298033T4 (da) 2023-10-02
IL255697B1 (en) 2023-07-01
EP3770168A1 (en) 2021-01-27
EA201792420A1 (ru) 2018-04-30
HUE051661T2 (hu) 2021-03-29
JP2021176326A (ja) 2021-11-11
EA035618B1 (ru) 2020-07-16
HK1252643A1 (en) 2019-05-31
JP7047172B2 (ja) 2022-04-04
EP3298033B1 (en) 2020-08-05
CN107995913A (zh) 2018-05-04
FI3298033T4 (fi) 2023-09-22
US20170166622A1 (en) 2017-06-15
US20210206827A9 (en) 2021-07-08
US20180244747A1 (en) 2018-08-30
AU2016264323A8 (en) 2017-12-21
US20200362011A1 (en) 2020-11-19
PL3298033T5 (pl) 2023-10-30
CN114634943A (zh) 2022-06-17
US11028142B2 (en) 2021-06-08
EA202090931A2 (ru) 2020-07-31
ES2819976T5 (es) 2024-02-23
EA202090931A3 (ru) 2020-10-30
US20240301026A1 (en) 2024-09-12
US20180251514A1 (en) 2018-09-06
PT3298033T (pt) 2020-09-22
ZA201708000B (en) 2025-04-30
CN107995913B (zh) 2022-02-11
ES2819976T3 (es) 2021-04-19
JP2023085509A (ja) 2023-06-20
EP3298033A1 (en) 2018-03-28
JP7262535B2 (ja) 2023-04-21
EP3298033A4 (en) 2018-10-24
US10358474B2 (en) 2019-07-23
JP2018515123A (ja) 2018-06-14
CA2986254A1 (en) 2016-11-24
PL3298033T3 (pl) 2021-02-22
US10442849B2 (en) 2019-10-15
US20230235010A1 (en) 2023-07-27
IL255697B2 (en) 2023-11-01
JP2021184749A (ja) 2021-12-09
AU2016264323A1 (en) 2017-12-14
MX2017014822A (es) 2018-04-30
BR112017024757A2 (pt) 2018-11-13
AU2021203052A1 (en) 2021-06-10
EP3466967A1 (en) 2019-04-10
SG10201914069SA (en) 2020-03-30
US11965012B2 (en) 2024-04-23
WO2016187349A1 (en) 2016-11-24
IL255697A (en) 2018-01-31

Similar Documents

Publication Publication Date Title
US11965012B2 (en) Compositions and methods for TCR reprogramming using fusion proteins
AU2019203955B2 (en) Multipartite signaling proteins and uses thereof
KR102319845B1 (ko) ์กฐ๋ฅ˜ ์ˆ™์ฃผ ์„ธํฌ์— ๋Œ€ํ•œ crispr-cas ์‹œ์Šคํ…œ
KR20210108423A (ko) ์•„๋ฐ๋…ธ ๊ด€๋ จ ๋ฐ”์ด๋Ÿฌ์Šค (aav) ์ƒ์‚ฐ์ž ์„ธํฌ์ฃผ ๋ฐ ๊ด€๋ จ ๋ฐฉ๋ฒ•
KR102006527B1 (ko) ์ „๋ฆฝ์„ -์—ฐ๊ด€ ํ•ญ์›์˜ ๋ฐœํ˜„์„ ์œ„ํ•œ ๋ฒกํ„ฐ
KR20100087303A (ko) ์ƒ๋ฌผ์น˜๋ฃŒํ•™์  ๋ถ„์ž๋ฅผ ๋ฐœํ˜„์‹œํ‚ค๊ธฐ ์œ„ํ•œ ์น˜๋ฃŒํ•™์  ์œ ์ „์ž-์Šค์œ„์น˜ ์ž‘์ œ๋ฌผ ๋ฐ ์ƒ๋ฌผ๋ฐ˜์‘๊ธฐ, ๋ฐ ์ด์˜ ์šฉ๋„
KR20230019063A (ko) C9orf72 ์—ฐ๊ด€ ์งˆํ™˜์˜ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ์‚ผ์ค‘ ๊ธฐ๋Šฅ ์•„๋ฐ๋…ธ-์—ฐ๊ด€ ๋ฐ”์ด๋Ÿฌ์Šค (aav) ๋ฒกํ„ฐ
CN114026242A (zh) ๅ…ทๆœ‰้ซ“้ž˜่›‹็™ฝ้›ถๅฏๅŠจๅญ็š„aav่ฝฝไฝ“ๅŠๅ…ถ็”จไบŽๆฒป็–—้›ชๆ—บ็ป†่ƒž็›ธๅ…ณ็–พ็—…ๅฆ‚charcot-marie-tooth็–พ็—…็š„็”จ้€”
KR20240037185A (ko) ํ‚ค๋ฉ”๋ผ ๊ณต๋™์ž๊ทน ์ˆ˜์šฉ์ฒด, ์ผ€๋ชจ์นด์ธ ์ˆ˜์šฉ์ฒด, ๋ฐ ์„ธํฌ ๋ฉด์—ญ์น˜๋ฃŒ์—์„œ์˜ ์ด์˜ ์šฉ๋„
KR20230117327A (ko) ๊ฐ€์šฉ์„ฑ ์•Œ์นผ๋ฆฌ์„ฑ ํฌ์ŠคํŒŒํƒ€์ œ ์ž‘์ œ๋ฌผ ๋ฐ ๊ฐ€์šฉ์„ฑ ์•Œ์นผ๋ฆฌ์„ฑ ํฌ์ŠคํŒŒํƒ€์ œ ์ž‘์ œ๋ฌผ์„ ์ธ์ฝ”๋”ฉํ•˜๋Š” ํด๋ฆฌ๋‰ดํด๋ ˆ์˜คํ‹ฐ๋“œ๋ฅผ ํฌํ•จํ•˜๋Š” ๋ฐœํ˜„ ๋ฒกํ„ฐ
AU2020344628A1 (en) Compositions and methods for TCR reprogramming using fusion proteins
AU2017233862B2 (en) Methods and compositions for increased double stranded RNA production
KR20240022571A (ko) Rna-๊ฐ€์ด๋“œ๋œ ์ดํŽ™ํ„ฐ ๋™์›์„ ์œ„ํ•œ ์‹œ์Šคํ…œ, ๋ฐฉ๋ฒ• ๋ฐ ์„ฑ๋ถ„
AU2020327783B2 (en) Oncolytic vaccinia virus
US20240165154A1 (en) Methods and agents for modulating adoptive immunotherapy
CA2522166C (en) Lambda integrase mutein for use in recombination
HK40091834A (en) Methods and compositions for increased double stranded rna production
HK40049685A (en) Adeno-associated virus (aav) producer cell line and related methods

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 31 , NO 49 , PAGE(S) 7157 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME TCR2 THERAPEUTICS, INC., APPLICATION NO. 2016264323, UNDER INID (71) CORRECT THE APPLICANT NAME TO TCR2 THERAPEUTICS INC.

FGA Letters patent sealed or granted (standard patent)